The spread of novel coronavirus infections is starting to make one thing clear: More vaccine investment is needed, the CEO of Asia's biggest drugmaker said.

"The world has to be more proactive than reactive," Christophe Weber, CEO of Takeda Pharmaceutical Co., said in an interview.

Although vaccine sales totaled $54.2 billion in 2019, that was less than 5 percent of total global revenue for pharmaceutical companies, according to data from Statista.